A5035397040- Prostate Cancer Treatment and Research
- Prostate Cancer Diagnosis and Treatment
- Endometrial and Cervical Cancer Treatments
- Advanced Radiotherapy Techniques
- Radiomics and Machine Learning in Medical Imaging
- MRI in cancer diagnosis
- Sarcoma Diagnosis and Treatment
- Spectroscopy Techniques in Biomedical and Chemical Research
- Medical Imaging Techniques and Applications
- Colorectal and Anal Carcinomas
- Cancer Immunotherapy and Biomarkers
- Bladder and Urothelial Cancer Treatments
- Surgical site infection prevention
- Advances in Oncology and Radiotherapy
- Cancer Diagnosis and Treatment
- Cervical Cancer and HPV Research
- Radiopharmaceutical Chemistry and Applications
- Urological Disorders and Treatments
- Neuroendocrine Tumor Research Advances
- Urinary and Genital Oncology Studies
- Esophageal Cancer Research and Treatment
- Ovarian cancer diagnosis and treatment
- Reconstructive Surgery and Microvascular Techniques
- Optical Polarization and Ellipsometry
- Lung Cancer Diagnosis and Treatment
Moffitt Cancer Center
2015-2025
St. Barnabas Hospital
2021
Centro de Información y Desarrollo de la Mujer
2021
University of South Florida
2009-2018
Radiation Oncology Associates
2017
Oregon State University
2016
McLaren Regional Medical Center
2016
University of Tampa
2015
National Institutes of Health
2000-2009
National Institute of Diabetes and Digestive and Kidney Diseases
2000-2005
Site-specific investigations of the role radiomics in cancer diagnosis and therapy are emerging. We evaluated reproducibility radiomic features extracted from 18 Flourine-fluorodeoxyglucose (18 F-FDG) PET images for three parameters: manual versus computer-aided segmentation methods, gray-level discretization, image reconstruction algorithms. Our cohort consisted pretreatment PET/CT scans 88 cervical patients. Two board-certified radiation oncologists manually segmented metabolic tumor...
In the phase III ALSYMPCA trial, metastatic castration-resistant prostate cancer (mCRPC) patients had few prior life-prolonging therapies. Following ALSYMPCA, which demonstrated radium-223 survival benefit, and before U.S. commercial availability, an expanded access program (EAP) providing early-access allowed therapies in current use.This II, open-label, single-arm, multicenter EAP (NCT01516762) enrolled with symptomatic mCRPC, ≥2 bone metastases, no lung, liver, or brain metastases....
Underwater robots beneath ocean waves can benefit from feedforward control to reduce position error. This letter proposes a method using model predictive (MPC) predict and counteract future disturbances an wave field. The MPC state estimator employs linear theory (LWT) solver approximate the component fluid dynamics under Wave data deployed buoys are used construct simulated is optimize set of actions by gradient descent along prediction horizon. optimized input minimizes global cost...
ADVERTISEMENT RETURN TO ISSUEPREVCommunicationNEXTPyruvate Formate-Lyase Activating Enzyme Is an Iron−Sulfur ProteinJoan B. Broderick, Randall E. Duderstadt, Daniel C. Fernandez, Kristi Wojtuszewski, Timothy F. Henshaw, and Michael K. JohnsonView Author Information Department of Chemistry, Amherst College Amherst, Massachusetts 01002 Chemistry Center for Metalloenzyme Studies University Georgia, Athens, Georgia 30602 Cite this: J. Am. Chem. Soc. 1997, 119, 31, 7396–7397Publication Date...
Abstract Background Personalized genomic classifiers have transformed the management of prostate cancer (PCa) by identifying most aggressive subsets PCa. Nevertheless, performance to risk classify African American men is thus far lacking in a prospective setting. Methods This study Decipher classifier for National Comprehensive Cancer Network low- and intermediate-risk Study-eligible non–African were matched men. Diagnostic biopsy specimens processed estimate scores. Samples accrued...
5536 Background: Pembrolizumab is approved for PD-L1+ but not PD-L1 negative metastatic, recurrent, or persistent cervical cancer. Response rates to single agent anti-PD-1/PD-L1 therapy have been modest with no responses noted in tumors. Methods: The study designed as a prospective, phase II multi-institutional trial of SBRT followed by atezolizumab (1200 mg intravenously q3 weeks). Key eligibility criteria included patients cancer at least 2 distinct lesions. primary objective was response...
Purpose To evaluate Lipiodol as a liquid, radio-opaque fiducial marker for image-guided radiation therapy (IGRT) bladder cancer. Materials and Methods Between 2011 2012, 5 clinical T2a-T3b N0 M0 stage II-III cancer patients were treated with maximal transurethral resection of tumor (TURBT) to 64.8 Gy in 36 fractions ± concurrent weekly cisplatin-based or gemcitabine chemotherapy. Ten 15mL Lipiodol, using 0.5mL per injection, was injected into submucosa circumferentially around the entire...
247 Background: The ALSYMPCA study (Parker, NEJM, 2013) was the basis for regulatory approval of Ra-223 treatment castrate-resistant prostate cancer (CRPC) patients (pts) with symptomatic bone metastases. aim this prospective EAP to monitor acute and long-term safety Ra-223. Pt profiles findings in setting are presented. Methods: In EAP, CRPC pts metastases who either received or were not eligible docetaxel 50 kBq/kg by injection q4wks 6 cycles. Primary endpts: ECOG PS, skeletal-related...
Abstract The purpose of this study was to evaluate whether a spacer inserted in the prerectal space could reduce modeled rectal dose and toxicity rates for patients with prostate cancer treated silico pencil beam scanning ( PBS ) proton therapy. A total 20 were included who received photon therapy (12 (DuraSeal™ gel) 8 without). Two treatment plans retrospectively created each patient using following arrangements: (1) lateral‐opposed LAT fields (2) left right anterior oblique LAO / RAO...